ClinicalTrials.gg
CompletedNCT00163202CAPUpdated Feb 18, 2021

Comparative Atorvastatin Pleiotropic Effects

A Phase 4 interventional study of Blood samples and Atorvastatin in Coronary Arteriosclerosis and Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 74 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 33 studies testing atorvastatin in Coronary Artery Disease — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Coronary Artery Disease.

Enrollment
6th of 33
330 · median 120
Started
2002
with 1 other
Phase 4
19 of 33
1 open now
Registered
2nd of 33
by date
Lead sponsor
3 of 33
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 33 studies testing atorvastatin in Coronary Artery Disease, this one is the 6th largest by enrollment, is one of 2 that started in 2002, is one of 19 in phase 4, and was the 2nd registered.

Coronary Artery Disease

4,865 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 33 studies testing atorvastatin in Coronary Artery Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About atorvastatin

Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing atorvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented coronary artery disease.

03

Conditions studied

  • Coronary Arteriosclerosis
  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects of age of majority to \< 80 years
  • Subjects with LDL-C > 0.5 g/L (1.29 mmol/L) and \< 1.5 g/L (3.87 mmol/L), TG \< 4.00 g/L (4.56 mmol/L) and hs-CRP >1.5 mg/L and \< 15 mg/L
  • Subjects with a documented coronary artery disease.

Exclusion criteria

Exclusion Criteria:

  • Female subjects of without
  • Subjects with secondary hyperlipidemia
  • Diabetic subjects receiving insulin
  • Subjects with a to statin therapy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
330 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Percentages changes of the hs-CRP between baseline (means between week-2 to -1 and week 0 (V2) values) and week 26 (V5).

Secondary outcomes

  1. 1/ the percentage change at visit 3 (5-week treatment), visit 4 (13-week-treatment) and visit 5 (26-week treatment) from baseline value in triglycerides, total cholesterol; HDL-cholesterol, LDL-cholesterol, apolipoprotein B 2/ the percentage change at

07

Study locations

74 sites
  • Pfizer Investigational Site
    Calgary, Alberta T2E 7C5, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2S2, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia v6z 1y6, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3E 0Z3, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Pfizer Investigational Site
    London, Ontario N6G 2V2, Canada
  • Pfizer Investigational Site
    Oshawa, Ontario L1J 2K1, Canada
  • Pfizer Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • Pfizer Investigational Site
    Weston, Ontario M9N 1W4, Canada
  • Pfizer Investigational Site
    Chicoutimi, Quebec G7H 5H6, Canada
  • Pfizer Investigational Site
    Laval, Quebec H7V 2T8, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 1C8, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H1T 2M4, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2W 1R7, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H4J 1C5, Canada
  • Pfizer Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Pfizer Investigational Site
    Ste-foy, Quebec G1V 4G2, Canada
  • Pfizer Investigational Site
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Pfizer Investigational Site
    Brno-Bohunice, 63900, Czechia
  • Pfizer Investigational Site
    Jindrichuv Hradec, 377 38, Czechia
  • Pfizer Investigational Site
    Prague 2, 120 00, Czechia
  • Pfizer Investigational Site
    Prague 2, 128 08, Czechia
  • Pfizer Investigational Site
    Prague 5, 150 06, Czechia
  • Pfizer Investigational Site
    Clermont-ferrand, Cedex 63003, France
  • Pfizer Investigational Site
    Langres, Cedex 52206, France
  • Pfizer Investigational Site
    Besancon, 25030, France
  • Pfizer Investigational Site
    Brest, 29609, France
  • Pfizer Investigational Site
    Chambery, 73000, France
  • Pfizer Investigational Site
    Clamart, 92141, France
  • Pfizer Investigational Site
    Clermont-ferrand, 63003, France
  • Pfizer Investigational Site
    Creil, 60100, France
  • Pfizer Investigational Site
    Dijon, 21034, France
  • Pfizer Investigational Site
    Evecquemont, 78740, France
  • Pfizer Investigational Site
    GAP, 05000, France
  • Pfizer Investigational Site
    Henin-beaumont, 62256, France
  • Pfizer Investigational Site
    Le Kremlin Bicetre Cedex, 94275, France
  • Pfizer Investigational Site
    Lille, 59037, France
  • Pfizer Investigational Site
    Marseille Cedex 05, 13385, France
  • Pfizer Investigational Site
    Metz Cedex 01, 57038, France
  • Pfizer Investigational Site
    Monaco, 98000, France
  • Pfizer Investigational Site
    Montpellier, 34295, France
  • Pfizer Investigational Site
    Mulhouse, 68070, France
  • Pfizer Investigational Site
    Nancy, 54000, France
  • Pfizer Investigational Site
    Nantes Saint Herblain, 44805, France
  • Pfizer Investigational Site
    Paris Cedex 05, 75230, France
  • Pfizer Investigational Site
    Paris Cedex 15, 75908, France
  • Pfizer Investigational Site
    Paris Cedex 18, 75877, France
  • Pfizer Investigational Site
    Paris, 75015, France
  • Pfizer Investigational Site
    Paris, 75018, France
  • Pfizer Investigational Site
    Pessac, 33064, France
  • Pfizer Investigational Site
    Poissy, 78303, France
  • Pfizer Investigational Site
    Pontoise, 95300, France
  • Pfizer Investigational Site
    Roubaix, 59056, France
  • Pfizer Investigational Site
    Saint Michel, 16470, France
  • Pfizer Investigational Site
    Thionville, 57100, France
  • Pfizer Investigational Site
    Toulouse, 31403, France
  • Pfizer Investigational Site
    Tourcoing, 59200, France
  • Pfizer Investigational Site
    Vandoeuvre Les Nancy, 54500, France
  • Pfizer Investigational Site
    Vandoeuvre, 54511, France
  • Pfizer Investigational Site
    Belchatow, 97-400, Poland
  • Pfizer Investigational Site
    Gdynia, 81-472, Poland
  • Pfizer Investigational Site
    Rawa Mazowiecka, 96-200, Poland
  • Pfizer Investigational Site
    Torun, 87-100, Poland
  • Pfizer Investigational Site
    Wroclaw, 50-420, Poland
  • Pfizer Investigational Site
    Zamosc, 22-400, Poland
  • Pfizer Investigational Site
    Bucharest, Sector 2 70000, Romania
  • Pfizer Investigational Site
    Bucharest, Sector 2 7000, Romania
  • Pfizer Investigational Site
    Bucharest, Sector 5 76251, Romania
  • Pfizer Investigational Site
    Moscow, 101953, Russian Federation
  • Pfizer Investigational Site
    Moscow, 121552, Russian Federation
  • Pfizer Investigational Site
    Volgograd, 400008, Russian Federation
  • Pfizer Investigational Site
    Bratislava, 81369, Slovakia
  • Pfizer Investigational Site
    Bratislava, 83348, Slovakia
08

References and documents

Publications

  • Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J; CAP Investigators. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023. PubMed 19167589 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 13, 2005
Start
Jun 2002
CompletionActual
Aug 2005
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00163202
Collaborators
MDS Pharma Services, Bio-Inova Life Sciences International
Responsible party
Sponsor
First posted
Sep 13, 2005
Start date
Jun 2002
Completion
Aug 2005
Last update
Feb 18, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atorvastatin

Start the discussion